Detalhe da pesquisa
1.
TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository.
J Transl Med
; 19(1): 269, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158060
2.
Development and interlaboratory evaluation of a NIST Reference Material RM 8366 for EGFR and MET gene copy number measurements.
Clin Chem Lab Med
; 57(8): 1142-1152, 2019 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31112502
3.
Criteria for the use of omics-based predictors in clinical trials.
Nature
; 502(7471): 317-20, 2013 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24132288
4.
A mutational comparison of adult and adolescent and young adult (AYA) colon cancer.
Cancer
; 124(5): 1070-1082, 2018 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29194591
5.
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.
Blood
; 123(8): 1214-7, 2014 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-24398326
6.
State of the Science and Future Directions for Liquid Biopsies in Drug Development.
Oncologist
; 25(9): 730-732, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32510742
7.
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
Cancer Cell
; 9(3): 157-73, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16530701
8.
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
JCO Precis Oncol
; 8: e2300454, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591867
9.
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
JCO Precis Oncol
; 8: e2300407, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603650
10.
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
JCO Precis Oncol
; 8: e2300406, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603651
11.
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Clin Cancer Res
; 30(7): 1273-1280, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38433347
12.
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.
BMC Med
; 11: 220, 2013 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24228635
13.
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Clin Cancer Res
; 29(8): 1477-1483, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36853016
14.
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
J Natl Cancer Inst
; 115(11): 1355-1363, 2023 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37228094
15.
The NCI-MATCH trial: lessons for precision oncology.
Nat Med
; 29(6): 1349-1357, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37322121
16.
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2.
JCO Precis Oncol
; 7: e2200421, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37053535
17.
Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors.
NPJ Precis Oncol
; 6(1): 63, 2022 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36068285
18.
Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F.
J Clin Oncol
; 40(14): 1552-1561, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35133871
19.
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
J Clin Oncol
; 40(20): 2235-2245, 2022 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363510
20.
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
J Clin Oncol
; 40(20): 2224-2234, 2022 07 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35353553